Current Crizotinib News and Events

Current Crizotinib News and Events, Crizotinib News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 3 | 120 Results
Cabozantinib most effective treatment for metastatic papillary kidney cancer
In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer - findings expected to change medical practice. (2021-02-13)

Patient-reported outcomes from the randomized phase III CROWN study of first-line Lorlatinib versus in ALK+ NSCLC
Patient-reported outcomes from the phase III CROWN study showed that time to treatment deterioration (TTD) in pain in chest, dyspnea, and cough was comparable between those who received lorlatinib and patients who took crizotinib. The research was presented today at the International Association for the Study of Lung Cancer's 2020 World Conference on Lung Cancer Singapore. (2021-01-31)

Phase 3 eXalt3 study shows significantly longer progression-free survival
Patients with non-small cell lung cancer (NSCLC) carrying anaplastic lymphoma kinase (ALK) gene alterations who received ensartinib experienced substantially longer progression-free survival than a matched group of patients who received crizotinib. (2020-08-08)

Entrectinib effective, well-tolerated against ROS1 and NTRK lung cancers, especially with brain metastases
Pooled analysis of three phase 1 and 2 clinical trials show that the drug entrectinib is effective and well-tolerated against advanced ROS1 and NTRK fusion-positive non-small cell lung cancers (NSCLC). (2019-12-13)

National lung matrix trial (NLMT)
The largest stratified medicine dataset of non-small cell lung cancer patients indicates further molecular stratifications could benefit from targeted therapies, according to research presented today at the IASLC 2019 World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer. (2019-09-09)

Pairing targeted drugs for breast and lung cancer could overcome treatment resistance
Targeted drugs for breast and lung cancer could be used together to overcome resistance to treatment in several different tumour types, a new study shows. Scientists discovered that when the breast cancer drug palbociclib was combined with the lung cancer drug crizotinib, the two-drug combination was significantly more effective against cancer cells in the laboratory than either drug used on its own. (2019-07-11)

ASCO: Entrectinib gets edge over crizotinib against ROS1+ lung cancer
Median time to treatment discontinuation (TTD) on crizotinib was 8.8 months; TTD of patients using entrectinib was 14.6 months. Compared with patients on entrectinib, patients on crizotinib had an additional 44 percent chance that their cancer would resume its growth. (2019-05-30)

ASCO 2019: 40-50 percent response rate for brigatinib after other next-gen ALK inhibitors
University of Colorado Cancer Center study presented at ASCO 2019 shows that brigatinib remains effective even after treatment with another next-generation ALK inhibitor (2019-05-30)

Rare pulmonary side effects of brigatinib often resolve without treatment discontinuation
'This study shows that [rare pulmonary side effects of brigatinib] can disappear within days despite continued exposure to the drug,' says D. Ross Camidge, M.D., Ph.D. (2019-05-21)

Tobacco use makes precancerous cells that fertilize cancer growth
Inhibiting EGFR along with PI3K may negate EGFR escape route that precancerous cells provide to cancer cells to avoid PI3K inhibitors. (2019-04-01)

Patients now living a median 6.8 years after stage IV ALK+ lung cancer diagnosis
Stage IV ALK+ lung cancer patients treated at UCHealth University of Colorado Hospital between 2009 and 2017 had median overall survival of 6.8 years. (2018-12-31)

Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer
'In 2017, alectinib, another next generation ALK-inhibitor, showed that it was superior to crizotinib in the first-line setting through the ALEX trial and now, in 2018, brigatinib is set to join alectinib as a 1st line option for ALK positive lung cancer,' said D. Ross Camidge, M.D., Ph.D., Joyce Zeff Chair in Lung Cancer Research at the University of Colorado Cancer Center and the lead author of ALTA-1L. (2018-09-25)

Promising phase 1/2 results for entrectinib against ROS1+ non-small cell lung cancer
Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer (NSCLC) presented on the press program of the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer show a response rate of 77.4 percent for 53 patients evaluable for response, with median duration of response of 24.6 months. (2018-09-24)

Is your lung cancer really ROS1-negative?
CU Cancer Center study shows that three common laboratory tests used to determine ROS1 status may return false-negative results, meaning that some patients who could benefit from ROS1-directed therapy may be slipping through the cracks. (2018-08-08)

Brain metastases common and difficult to treat in ROS1 lung cancer
Brain metastases were found to be fairly common in stage IV ROS1-positive cancers and in 47 percent of ROS1 patients, the brain was the first and only site of progression. (2018-07-10)

ASCO: ALEX trial results show alectinib further outpacing crizotinib in ALK+ NSCLC
Updated data presented at ASCO 2018 further consolidate alectinib as the standard-of-care for first-line treatment of ALK+ non-small cell lung cancer. (2018-06-03)

ASCO18: Updated Phase 1 results of crizotinib against MET-amplified lung cancer
By lowering the bar for 'high MET amplification,' a study suggests that crizotinib may benefit more MET-amplified non-small cell lung cancer patients than previously thought. (2018-06-03)

Alectinib provides longer symptom improvement than crizotinib in ALK-positive lung cancer
The findings of the ALEX trial presented at the ELCC (European Lung Cancer Congress) 2018 in Geneva, Switzerland, support the use of alectinib as the new standard of care in the frontline treatment of ALK-positive lung cancer. Alectinib was found to provide longer symptom improvement than crizotinib in ALK-positive non-small-cell lung cancer. (2018-04-12)

Two Colorado studies find resistance mechanisms in ALK+ and ROS1+ cancers
In one of 12 ROS1+ samples and 15 of 43 ALK+ samples, new kinases had been altered to allow treatment resistance. However, 'we found a lot of stuff besides kinase mutations,' a researcher says. 'What we're trying to say is that resistance happens in a lot of different ways and we need to be thinking about all the genetic and non-genetic changes that can occur.' (2018-04-10)

ENDO 18: New model, new drugs, and a 'remarkable' response in adrenal cancer
Two University of Colorado Cancer Center studies presented at ENDO 2018 use new models to identify genetic targets and test promising treatments in adrenal cancer. One patient was treated with the immunotherapy pembrolizumab and now more than a year after starting treatment remains on the drug with 77 percent tumor reduction and no new metastases. (2018-03-19)

NEJM reports positive results for larotrectinib against TRK-fusion cancer
55 patients representing 17 cancer types tested positive for TRK fusion and were treated with larotrectinib. Overall response rate was 75 percent. (2018-02-22)

Adding crizotinib to radiation therapy may help preserve hearing in patients with NF2
A Massachusetts General Hospital research team reports that the use of crizotinib to block a specific molecular pathway both enhanced the radiosensitivity of tumors in mouse models of NF2, allowing a reduction in radiation dosage, and inhibited the growth of cultured tumor cells from NF2 patients. (2018-02-05)

New guidelines on clinical trial design for patients with brain metastases
New guidelines from an international, multidisciplinary group published in the journal Lancet Oncology describe how to most appropriately address cancer patients with CNS involvement within clinical trials of anti-cancer drugs. (2017-12-29)

ALEX study shows alectinib 600 mg more effective than crizotinib in Asian cancer patients
A subanalysis of the phase III ALEX study has shown that alectinib 600 mg twice daily is more effective than standard of care crizotinib in Asian patients with anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC), researchers report at the ESMO Asia 2017 Congress. (2017-11-17)

Lung cancer driver ALK-fusion found in melanoma
A University of Colorado Cancer Center study published today in the journal Molecular Cancer Therapeutics finds a genetic change called ALK-fusion in a patient sample of a melanoma subtype called mucosal melanoma. When researchers treated a tumor grown from this sample with the drugs crizotinib and ceritinib - both FDA approved to treat ALK-positive lung cancer - the tumor responded dramatically. (2017-10-23)

Alectinib: ALEX and ALUR trials show CNS benefit in NSCLC
Data from two separate phase 3 studies to be presented at the ESMO 2017 Congress in Madrid, show alectinib's particular central nervous system (CNS) activity in patients with advanced non-small cell lung cancer involving a mutation of the anaplastic lymphoma kinase gene (ALK-positive NSCLC). (2017-09-05)

New approach to genetic testing leads to dramatic response in MET fusion lung cancer
University of Colorado Cancer Center case study published today in the journal JCO Precision Oncology tests for alterations in many genes simultaneously, resulting in the first published report describing successful targeting of MET fusion in a lung cancer patient. (2017-08-30)

Does stronger initial response to cancer treatment predict longer overall survival?
It seems like such a simple question: Do patients whose tumors shrink more in response to targeted treatment go on to have better outcomes than patients whose tumors shrink less? But the implications of a recent study demonstrating this relationship are anything but simple and could influence both the design of future clinical trials and the goals of oncologists treating cancer. (2017-08-14)

Alectinib potential new standard of care for ALK-positive non-small lung cancer
Results of a 303-patient, multi-national phase III clinical trial known as ALEX published today in the New England Journal of Medicine and presented concurrently at the American Society for Clinical Oncology (ASCO) Annual Meeting 2017 argue for alectinib replacing crizotinib as first-line standard of care in advanced ALK-positive non-small cell lung cancer. (2017-06-06)

Alectinib halts lung cancer growth more than a year longer than crizotinib
Findings from a phase III clinical trial point to a more effective initial treatment for patients with ALK-positive non-small cell lung cancer (NSCLC). Compared to the current standard of care crizotinib (Xalkori), the newer ALK inhibitor alectinib (Alecensa) halted cancer growth for a median of 15 months longer and caused fewer severe side effects. (2017-06-05)

Brigatinib first to offer over 1-year control of ALK-positive lung cancer post-crizotinib
Results of a multi-center, 222-person phase 2 clinical trial of the next-generation ALK inhibitor, brigatinib at 180mg/day, used after failure of crizotinib showed a 54 percent response rate and 12.9 month progression-free survival. (2017-05-17)

Serial analysis of CTCs may provide biomarker predictive of NSCLC response to crizotinib
Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression-free survival. (2017-05-01)

Next-generation microscopy
A novel microscopy method allows unprecedented insights into the spatial organization and direct interactions of immune cells within blood and liquid multi-lineage tissues. The assay, called 'Pharmacoscopy,' is able to determine the immunomodulatory properties of drugs within large libraries on immune cells in high resolution and high throughput. Introduced in Nature Chemical Biology, Pharmacoscopy enables new possibilities for drug discovery, particularly in cancer immunotherapy, personalized medicine, and research on signaling pathways of the immune system. (2017-04-24)

Bronchial carcinoma: Added benefit of crizotinib not proven
The dossier contains no data or no suitable data on ROS1-positive, advanced non-small cell lung cancer. Results on ALK-positive tumors are not applicable. (2017-01-11)

Mayo Clinic investigators pinpoint cause, possible treatment for rare form of sarcoma
Researchers at Mayo Clinic Center for Individualized Medicine have discovered a potential cause and a promising new treatment for inflammatory myofibroblastic tumors, a rare soft tissue cancer that does not respond to radiation or chemotherapy. (2016-11-22)

Ceritinib provides longer PFS than chemo in phIII trial of ALK rearranged lung cancer
Ceritinib provides longer progression-free survival than chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND-5 study presented today at the ESMO 2016 Congress in Copenhagen. (2016-10-09)

Ceritinib improves progression-free survival in phase 3 trial of ALK rearranged lung cancer
Ceritinib provides longer progression-free survival than chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND-5 study presented today at the ESMO 2016 Congress in Copenhagen. (2016-10-09)

Crizotinib in bronchial carcinoma: New data not informative
After expiry of the limitation period, the manufacturer presented results from a later data cut-off. Due to frequent treatment switching, these cannot be interpreted in a meaningful way. (2016-10-06)

Nivolumab in advanced lung cancer: Indication of major added benefit
Patients with advanced nonsquamous NSCLC who have already undergone chemotherapy survive longer with the drug than with docetaxel. (2016-08-18)

CTCA Western clinical research director authors five innovative studies presented at ASCO
Advances in lung cancer, ovarian cancer and new immunotherapy treatments are among the scientific studies presented this year at ASCO by Dr. Glen Weiss, Director of Clinical Research at Cancer Treatment Centers of America® (CTCA) at Western Regional Medical Center (Western). Dr. Weiss has overseen a substantial number of innovative clinical trials since he began supervising clinical research at CTCA Western in 2013. (2016-06-03)

Page 1 of 3 | 120 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.